NeuralStockNeuralStock
HomeResearch mode

PFE

Pfizerstock
$29.440.79% today

PFE · 90-day price history

Market cap

$161.9B

P/E

37.4

Div yield

6.06%

Industry

Drug Manufacturers - General

Exchange

NYSE

Website ↗

Prediction models

All predictions →

Trend follower

Horizon: 1 week

up
Signal strength0.19
Historical accuracy40%
92 predictions · 12mBaseline 45%
How this works

Compares a 10-day vs 50-day moving average. When the short-term average rises above the long-term average, the trend is up.

Not financial advice. Past accuracy does not guarantee future results.

Momentum

Horizon: 1 week

up
Signal strength0.28
Historical accuracy25%
92 predictions · 12mBaseline 45%
How this works

Uses RSI (a gauge of recent buying/selling intensity) and 5-day rate-of-change to judge whether the stock has been pushed too far in one direction.

Not financial advice. Past accuracy does not guarantee future results.

Statistical trend

Horizon: 1 month

up
Signal strength0.50
Historical accuracy35%
75 predictions · 12mBaseline 40%
How this works

Fits a trend line through the last 60 days of prices and measures how far the current price has strayed from it.

Not financial advice. Past accuracy does not guarantee future results.

Multi-factor + news

Horizon: 1 week

AI + NEWS
up
Signal strength0.27
Historical accuracy39%
31 predictions · 12mBaseline 45%

Accuracy reflects technical signals only. News sentiment is live.

How this works

Combines trend (25%), momentum (25%), volume (15%), and AI-analysed news sentiment (35%) from your trusted sources into one score.

Not financial advice. Past accuracy does not guarantee future results.

Bull / Bear thesis

AI analysis
Bull case●

High-yield dividend appeal in rising-rate environment

6.3% yield highlighted as attractive for income investors; dividend raised dividend for 16 years

Yahoo

Healthcare sector rotation supporting gains

Up 0.79% as money rotates from AI into healthcare; Moderna rallying 6% alongside

Price action

Obesity drug pipeline expansion underway

Key readouts expected over next year for obesity portfolio to offset Humira patent cliff

Yahoo
Bear case●

Humira patent cliff creating revenue headwind

Comparing to AbbVie shows peers offsetting losses faster; PFE rebuilding pipeline

Yahoo

Modest stock move despite sector strength

Up only 0.79% while healthcare rotates and Moderna up 6%

Price action

Execution risk on obesity drug readouts

Multiple pipeline readouts expected but no guarantee of success or market size

Price action

AI-generated from recent news and price action. Not financial advice. Educational only.

Seasonality

~5y of history

Avg return by month · %

JFMAMJJASOND

This month historically: -2.17% on average, up 20% of 5 years.

Avg return by weekday · %

MonTueWedThuFri

Historical pattern only — seasonality is not a prediction and often breaks.

Recent news

2 High-Yield Dividend Stocks Worth Buying Before 2026 Ends

Yahoo · Oct 15

Positions PFE as attractive income play with 6.3% yield available before year-end.

Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher

Yahoo · Oct 15

Shows broader healthcare momentum pulling PFE higher alongside mRNA competitors.

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Yahoo · Oct 15

Obesity drug strategy presented as PFE's answer to AbbVie's Humira patent cliff challenge.

AI research companion

AI Research Companion

Loading…

Ready to paper trade PFE?

Switch to Portfolio mode to buy and sell with $100k of simulated funds.

Open Portfolio mode →